Jing Zhang1,2, Eunjin Oh1, Karla E Merz1, Arianne Aslamy1,3, Rajakrishnan Veluthakal1, Vishal A Salunkhe1, Miwon Ahn1, Ragadeepthi Tunduguru1,4, Debbie C Thurmond5. 1. Department of Molecular and Cellular Endocrinology, Diabetes and Metabolism Research Institute, Beckman Research Institute of City of Hope, 1500 E. Duarte Road, Duarte, CA, 91010, USA. 2. Anwita Biosciences Inc, San Carlos, CA, USA. 3. Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN, USA. 4. Department of Diabetes Complications and Metabolism, Diabetes and Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA, USA. 5. Department of Molecular and Cellular Endocrinology, Diabetes and Metabolism Research Institute, Beckman Research Institute of City of Hope, 1500 E. Duarte Road, Duarte, CA, 91010, USA. dthurmond@coh.org.
Abstract
AIMS/HYPOTHESIS: Skeletal muscle accounts for >80% of insulin-stimulated glucose uptake; dysfunction of this process underlies insulin resistance and type 2 diabetes. Insulin sensitivity is impaired in mice deficient in the double C2 domain β (DOC2B) protein, while whole-body overexpression of DOC2B enhances insulin sensitivity. Whether insulin sensitivity in the skeletal muscle is affected directly by DOC2B or is secondary to an effect on other tissues is unknown; the underlying molecular mechanisms also remain unclear. METHODS: Human skeletal muscle samples from non-diabetic or type 2 diabetic donors were evaluated for loss of DOC2B during diabetes development. For in vivo analysis, new doxycycline-inducible skeletal-muscle-specific Doc2b-overexpressing mice fed standard or high-fat diets were evaluated for insulin and glucose tolerance, and insulin-stimulated GLUT4 accumulation at the plasma membrane (PM). For in vitro analyses, a DOC2B-overexpressing L6-GLUT4-myc myoblast/myotube culture system was coupled with an insulin resistance paradigm. Biochemical and molecular biology methods such as site-directed mutagenesis, co-immunoprecipitation and mass spectrometry were used to identify the molecular mechanisms linking insulin stimulation to DOC2B. RESULTS: We identified loss of DOC2B (55% reduction in RNA and 40% reduction in protein) in the skeletal muscle of human donors with type 2 diabetes. Furthermore, inducible enrichment of DOC2B in skeletal muscle of transgenic mice enhanced whole-body glucose tolerance (AUC decreased by 25% for female mice) and peripheral insulin sensitivity (area over the curve increased by 20% and 26% for female and male mice, respectively) in vivo, underpinned by enhanced insulin-stimulated GLUT4 accumulation at the PM. Moreover, DOC2B enrichment in skeletal muscle protected mice from high-fat-diet-induced peripheral insulin resistance, despite the persistence of obesity. In L6-GLUT4-myc myoblasts, DOC2B enrichment was sufficient to preserve normal insulin-stimulated GLUT4 accumulation at the PM in cells exposed to diabetogenic stimuli. We further identified that DOC2B is phosphorylated on insulin stimulation, enhancing its interaction with a microtubule motor protein, kinesin light chain 1 (KLC1). Mutation of Y301 in DOC2B blocked the insulin-stimulated phosphorylation of DOC2B and interaction with KLC1, and it blunted the ability of DOC2B to enhance insulin-stimulated GLUT4 accumulation at the PM. CONCLUSIONS/ INTERPRETATION: These results suggest that DOC2B collaborates with KLC1 to regulate insulin-stimulated GLUT4 accumulation at the PM and regulates insulin sensitivity. Our observation provides a basis for pursuing DOC2B as a novel drug target in the muscle to prevent/treat type 2 diabetes.
AIMS/HYPOTHESIS: Skeletal muscle accounts for >80% of insulin-stimulated glucose uptake; dysfunction of this process underlies insulin resistance and type 2 diabetes. Insulin sensitivity is impaired in mice deficient in the double C2 domain β (DOC2B) protein, while whole-body overexpression of DOC2B enhances insulin sensitivity. Whether insulin sensitivity in the skeletal muscle is affected directly by DOC2B or is secondary to an effect on other tissues is unknown; the underlying molecular mechanisms also remain unclear. METHODS:Human skeletal muscle samples from non-diabetic or type 2 diabetic donors were evaluated for loss of DOC2B during diabetes development. For in vivo analysis, new doxycycline-inducible skeletal-muscle-specific Doc2b-overexpressing mice fed standard or high-fat diets were evaluated for insulin and glucose tolerance, and insulin-stimulated GLUT4 accumulation at the plasma membrane (PM). For in vitro analyses, a DOC2B-overexpressing L6-GLUT4-myc myoblast/myotube culture system was coupled with an insulin resistance paradigm. Biochemical and molecular biology methods such as site-directed mutagenesis, co-immunoprecipitation and mass spectrometry were used to identify the molecular mechanisms linking insulin stimulation to DOC2B. RESULTS: We identified loss of DOC2B (55% reduction in RNA and 40% reduction in protein) in the skeletal muscle of human donors with type 2 diabetes. Furthermore, inducible enrichment of DOC2B in skeletal muscle of transgenic mice enhanced whole-body glucose tolerance (AUC decreased by 25% for female mice) and peripheral insulin sensitivity (area over the curve increased by 20% and 26% for female and male mice, respectively) in vivo, underpinned by enhanced insulin-stimulated GLUT4 accumulation at the PM. Moreover, DOC2B enrichment in skeletal muscle protected mice from high-fat-diet-induced peripheral insulin resistance, despite the persistence of obesity. In L6-GLUT4-myc myoblasts, DOC2B enrichment was sufficient to preserve normal insulin-stimulated GLUT4 accumulation at the PM in cells exposed to diabetogenic stimuli. We further identified that DOC2B is phosphorylated on insulin stimulation, enhancing its interaction with a microtubule motor protein, kinesin light chain 1 (KLC1). Mutation of Y301 in DOC2B blocked the insulin-stimulated phosphorylation of DOC2B and interaction with KLC1, and it blunted the ability of DOC2B to enhance insulin-stimulated GLUT4 accumulation at the PM. CONCLUSIONS/ INTERPRETATION: These results suggest that DOC2B collaborates with KLC1 to regulate insulin-stimulated GLUT4 accumulation at the PM and regulates insulin sensitivity. Our observation provides a basis for pursuing DOC2B as a novel drug target in the muscle to prevent/treat type 2 diabetes.
Authors: Jia Li; James Cantley; James G Burchfield; Christopher C Meoli; Jacqueline Stöckli; P Tess Whitworth; Himani Pant; Rima Chaudhuri; Alexander J A Groffen; Matthijs Verhage; David E James Journal: Diabetologia Date: 2014-07-09 Impact factor: 10.122
Authors: Hiroyuki Sano; Susan Kane; Eiko Sano; Cristinel P Mîinea; John M Asara; William S Lane; Charles W Garner; Gustav E Lienhard Journal: J Biol Chem Date: 2003-03-11 Impact factor: 5.157
Authors: Zhen Y Jiang; Qiong L Zhou; Kerri A Coleman; My Chouinard; Queta Boese; Michael P Czech Journal: Proc Natl Acad Sci U S A Date: 2003-06-13 Impact factor: 11.205
Authors: Karla E Merz; Ragadeepthi Tunduguru; Miwon Ahn; Vishal A Salunkhe; Rajakrishnan Veluthakal; Jinhee Hwang; Supriyo Bhattacharya; Erika M McCown; Pablo A Garcia; Chunxue Zhou; Eunjin Oh; Stephanie M Yoder; Jeffrey S Elmendorf; Debbie C Thurmond Journal: Front Endocrinol (Lausanne) Date: 2022-02-11 Impact factor: 5.555
Authors: Raya Sorkin; Margherita Marchetti; Emma Logtenberg; Melissa C Piontek; Emma Kerklingh; Guy Brand; Rashmi Voleti; Josep Rizo; Wouter H Roos; Alexander J Groffen; Gijs J L Wuite Journal: Biophys J Date: 2019-12-25 Impact factor: 4.033
Authors: Don T Li; Estifanos N Habtemichael; Omar Julca; Chloe I Sales; Xavier O Westergaard; Stephen G DeVries; Diana Ruiz; Bhavesh Sayal; Jonathan S Bogan Journal: Yale J Biol Med Date: 2019-09-20
Authors: Karla E Merz; Jinhee Hwang; Chunxue Zhou; Rajakrishnan Veluthakal; Erika M McCown; Angelica Hamilton; Eunjin Oh; Wenting Dai; Patrick T Fueger; Lei Jiang; Janice M Huss; Debbie C Thurmond Journal: Nat Commun Date: 2022-01-20 Impact factor: 17.694